Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intravenous InfusionsXGHA:IIL +8.86% Dividend Yield % is 0.00% as of Jul. 30, 2026. Among 512 Drug Manufacturers companies, Intravenous Infusions ranks worse than 195312.3% on this metric.
As of today (2026-07-30), the Trailing Annual Dividend Yield of Intravenous Infusions is 0.00%.
The historical rank and industry rank for Intravenous Infusions's Dividend Yield % or its related term are showing as below:
XGHA:IIL's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.965 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Intravenous Infusions Dividend Yield % Related Terms
Intravenous Infusions Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Intravenous Infusions's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Dividend Yield % Chart
Intravenous Infusions Annual Data
Trend
Dividend Yield %
Intravenous Infusions Semi-Annual Data
Dividend Yield %
XGHA:IIL vs PTLF, PCYN, YBAO: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intravenous Infusions Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Intravenous Infusions's Dividend Yield % falls into.
Intravenous Infusions (XGHA:IIL) has a Dividend Yield % of 0.00% as of Jul. 30, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 512 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Dividend Yield % too high?
Intravenous Infusions' current Dividend Yield % is 0.00%. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 512 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Intravenous Infusions' Dividend Yield % compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 512 companies for Dividend Yield %. This places Intravenous Infusions in the lower half of its industry. The industry median Dividend Yield % is 1.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.97, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Dividend Yield % is 0.00% as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
